Table 3.
Efficacy and safety outcomes at 30-day follow up.
| GPI (n=1143) | No GPI (n=1852) | Unadjusted OR (95% CI) | p-value | PMS with GPI (n=923) | PMS and no GPI (n=923) | PM sample OR (95% CI) | p-value | |
|---|---|---|---|---|---|---|---|---|
| MACE | 149 (13.0) | 167 (9.0) | 1.59 (1.24–2.09) | <0.001 | 85 (9.2) | 114 (12.3) | 0.72 (0.53–0.97) | 0.03 |
| Death | 65 (5.7) | 70 (3.8) | 1.53 (1.08–2.17) | 0.02 | 33 (3.6) | 51 (5.5) | 0.63 (0.40–0.90) | 0.04 |
| Reinfarction | 55 (4.8) | 59 (3.2) | 1.55 (1.06–2.25) | 0.02 | 39 (4.2) | 55 (5.9) | 0.68 (0.44–1.04) | 0.08 |
| Stroke | 14 (1.1) | 11 (0.6) | 2.07 (0.94–4.58) | 0.10 | 10 (1.1) | 4 (0.4) | 2.51 (0.78–8.04) | 0.12 |
| DST | 52 (4.5) | 57 (3.1) | 1.50 (1.02–2.21) | 0.04 | 32 (3.5) | 43 (4.7) | 0.74 (0.46–1.17) | 0.19 |
| ITVR | 15 (1.3) | 27 (1.5) | 0.90 (0.48–1.71) | 0.87 | 3 (0.3) | 4 (0.4) | 0.75 (0.16–3.35) | 0.73 |
| Total bleeding | 80 (7.0) | 75 (4.0) | 1.76 (1.27–2.43) | 0.001 | 50 (5.4) | 32 (3.5) | 1.59 (1.01–2.50) | 0.04 |
| Major bleeding | 13 (1.2) | 17 (0.9) | 1.24 (0.60–2.56) | 0.57 | 7 (0.7) | 7 (0.7) | 0.99 (0.34–2.85) | 0.99 |
| Minor bleeding | 32 (2.8) | 27 (1.4) | 2.01 (1.20–3.36) | 0.01 | 21 (2.3) | 13 (1.4) | 1.62 (0.81–2.27) | 0.17 |
| Minimal bleeding | 35 (3.0) | 31 (1.7) | 1.95 (1.19–3.20) | 0.008 | 22 (2.4) | 12 (1.3) | 2.13 (1.03–4.40) | 0.04 |
| Transfusion | 34 (2.9) | 31 (1.7) | 1.75 (1.05–2.92) | 0.03 | 17 (1.8) | 14 (1.5) | 1.21 (0.59–2.48) | 0.59 |
Values are n (%) unless otherwise stated.
DST, definite stent thrombosis; GPI, glycoprotein IIb/IIIa receptor inhibitor tirofiban; ITVR, ischaemia-driven target vessel revascularization; MACE, major adverse cardiovascular events; PMS, propensity-matched sample.